What is uMotif?
Established in 2012 and headquartered in London, UK, uMotif provides a patient-centered data capture platform designed for modern research initiatives. The company's technology aims to streamline data collection processes, enhancing the efficiency and accuracy of clinical studies and other research endeavors. The recent major enterprise-level funding indicates a strategic push for scaling operations and expanding its market reach.
How much funding has uMotif raised?
uMotif has raised a total of $25.5M across 1 funding round:
Private Equity
$25.5M
Private Equity (2022): $25.5M with participation from Athyrium Capital Management
Key Investors in uMotif
Athyrium Capital Management
Athyrium Capital Management is a leading investment management platform focused on structured investments in the global healthcare sector, investing in a diverse array of financial instruments and engaging in select special situations. With over $5 billion in capital invested, Athyrium leverages its extensive healthcare expertise and global network to provide financing solutions that support growth objectives for companies in the pharmaceutical, biotechnology, and healthcare services sectors.
What's next for uMotif?
The substantial enterprise-level funding and recent strategic investment suggest uMotif is poised for significant growth and expansion. This capital infusion will likely be directed towards enhancing its platform capabilities, broadening its client base, and potentially exploring new research verticals. The company's focus on patient-centered data capture positions it well to capitalize on the increasing demand for robust and reliable research data solutions in the healthcare and life sciences industries.
See full uMotif company page
